A 52-year-old woman from Bangalore presents with a 3.5 cm mass in the lower outer quadrant of her right breast with skin dimpling. On examination, she has fixed axillary lymph nodes and no clinical evidence of distant metastases. Biopsy confirms invasive lobular carcinoma, grade III. Staging imaging shows no M1 disease. She is HER2 positive and ER negative. The tumour is deemed potentially resectable. What is the most appropriate initial management strategy?

Explanation

## Clinical Staging & Assessment This patient has: - **T3 (3.5 cm) tumour with skin dimpling** (advanced local disease) - **Fixed axillary lymph nodes** = N2b/N3a (advanced nodal disease) - **No distant metastases** = M0 - **Overall stage: IIIB/IIIC** (locally advanced breast cancer, LABC) - **HER2 positive, ER negative** = HER2-enriched phenotype (aggressive) ## Why Neoadjuvant Therapy? ```mermaid flowchart TD A[Locally advanced breast cancer]:::outcome --> B{Resectable?}:::decision B -->|Yes, operable| C[Neoadjuvant chemotherapy + HER2-targeted therapy]:::action B -->|No, inoperable| D[Neoadjuvant therapy to convert to operable]:::action C --> E[Assess response at 4-6 weeks]:::decision E -->|Good response| F[Surgery: mastectomy + ALND]:::action E -->|Poor response| G[Reassess resectability]:::decision G -->|Still resectable| F G -->|Inoperable| H[Continue systemic therapy]:::action F --> I[Adjuvant therapy based on response]:::action ``` **Key Point:** Locally advanced breast cancer (stage III) is managed with **neoadjuvant (primary) systemic therapy** FIRST, followed by surgery. This approach: 1. **Downstages** the tumour and nodes, improving resectability 2. **Assesses chemosensitivity** in vivo 3. **Improves overall survival** compared to upfront surgery 4. **Allows breast-conserving surgery** in selected cases if good response **High-Yield:** The **NCCN, ASCO, and ESMO guidelines** all recommend neoadjuvant therapy for stage III breast cancer. HER2-positive disease requires **dual HER2 blockade** (trastuzumab + pertuzumab) or trastuzumab monotherapy during neoadjuvant phase. ## Neoadjuvant Regimen for HER2+ LABC | Component | Details | |-----------|----------| | **Chemotherapy** | Anthracycline-taxane based (e.g., AC → paclitaxel or docetaxel) | | **HER2 therapy** | Trastuzumab ± pertuzumab (dual blockade preferred) | | **Duration** | 4–6 cycles (12–18 weeks) | | **Reassessment** | Clinical and imaging at 4–6 weeks; pathologic complete response (pCR) is prognostic | **Clinical Pearl:** Skin dimpling indicates T3 disease (invasion of dermis or fixation to chest wall). Fixed axillary nodes indicate N2b/N3a. Together, these constitute **locally advanced disease requiring multimodal therapy**, not immediate surgery. **Mnemonic:** **LABC** = Locally Advanced Breast Cancer (stage III). Manage with **NAT** (Neoadjuvant Therapy) → Surgery → Adjuvant Therapy.